Randomised Study to Assess the Efficacy and Safety of Once-Daily Etravirine-Based Regimen as a Switching Strategy in HIV-Infected Patients Receiving a Protease Inhibitor–Containing Regimen. Etraswitch Study

BACKGROUND: Etravirine (ETR) was approved for patients with virological failure and antiretroviral resistance mutations. It has also shown antiviral efficacy in antiretroviral-naïve patients. However, data on the switching from protease inhibitors (PI) to ETR are lacking. METHODS: HIV-1-infected pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Echeverría, Patricia, Bonjoch, Anna, Puig, Jordi, Moltó, José, Paredes, Roger, Sirera, Guillem, Ornelas, Arelly, Pérez-Álvarez, Nuria, Clotet, Bonaventura, Negredo, Eugènia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913576/
https://www.ncbi.nlm.nih.gov/pubmed/24503952
http://dx.doi.org/10.1371/journal.pone.0084676

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913576/
https://www.ncbi.nlm.nih.gov/pubmed/24503952
http://dx.doi.org/10.1371/journal.pone.0084676

Ejemplares similares